H.C. Wainwright reiterates buy rating on Crinetics stock at $81 target

H.C. Wainwright maintained its Buy rating and $81 price target for Crinetics (CRNX), citing the company's robust drug discovery capabilities and pipeline, including key near-term drivers like the anticipated September 2025 launch of paltusotine for acromegaly and promising early-stage assets such as CRN12755 for Graves’ Disease. Despite a Q1 2025 revenue decline, Crinetics increased R&D spending by 43% and maintains a strong cash position expected to fund operations into 2029, supporting its strategic market expansion efforts.

Analysis

H.C. Wainwright has reaffirmed its Buy rating and an $81.00 price target for Crinetics Pharmaceuticals (CRNX), highlighting a significant valuation gap compared to its current price of $29.99. The core of this bullish thesis rests on the company's drug discovery capabilities and deep pipeline. While near-term value is primarily driven by paltusotine, which is anticipated for a September 2025 launch for acromegaly, and atumelnant, the firm emphasizes the long-term potential of early-stage assets like CRN12755 for Graves' Disease. This optimism is supported by the company's demonstrated strength in generating proof-of-mechanism data in Phase 1 studies, which can de-risk assets as they advance. Financially, Crinetics reported a Q1 2025 revenue decline to $400,000 from $600,000 year-over-year, which is offset by a strategic 43% increase in R&D expenses. The company's robust balance sheet, with a cash runway projected into 2029, provides substantial support for its innovation-focused strategy, including the build-out of commercial infrastructure and planned market expansion into Germany.

Key Decisions for Investors

• Investors should view Crinetics primarily as a long-term play on its clinical pipeline, where the substantial upside to the $81 price target is contingent on successful drug approvals and commercialization, starting with the FDA's decision on paltusotine.
• The decline in Q1 revenue is secondary to the company's financial stability; focus should be on the strong cash position which funds operations into 2029, enabling aggressive R&D spending and pre-commercial activities without near-term financing risk.
• Monitor key upcoming catalysts closely, particularly clinical data from atumelnant and early-stage assets, as positive results are critical to validating the pipeline's long-term value and justifying the current high analyst valuation.
• Consider the increased R&D spending as a positive leading indicator of the company's commitment to its pipeline, which is the primary value driver, rather than focusing on the negligible current revenue of this pre-commercial stage biotech.